Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.

Cardiovasc Diabetol · 2016 · PMC4818390 · PMID 27036865

Europe PMC DOI

hedged sentence

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

showed a trendP = 0.093so close (0.05 < p ≤ 0.1)

Although the shortening of the QT interval in this study was mainly associated with the increased HR, the QTc interval still showed a trend toward shortening after sitagliptin therapy (P = 0.093).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.